Topical treatment for vitiligo using a selective MC1R agonist
Vitiligo topical treatment applying a potent, highly selective MC1R agonist
This study is testing a new cream that might help people with vitiligo regain their skin color by targeting a specific receptor in the skin, and it will keep track of how well it works and how your skin feels during the treatment.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mc1r Ventures LLC NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-10759768 on NIH RePORTER |
What this research studies
This research focuses on developing a topical treatment for vitiligo, a skin condition characterized by the loss of pigment. The approach involves using a potent and selective agonist for the melanocortin-1 receptor (MC1R), which may help restore pigmentation in affected areas. The study aims to understand the mechanisms behind melanocyte destruction and explore how this treatment can promote repigmentation. Patients will be monitored for changes in skin pigmentation and overall skin health throughout the treatment period.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with vitiligo, particularly those who are young adults or children under 11 years old.
Not a fit: Patients with vitiligo who do not respond to topical treatments or have other underlying skin conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for individuals suffering from vitiligo, potentially improving their skin appearance and psychological well-being.
How similar studies have performed: Previous research has shown promise in using MC1R agonists for skin conditions, indicating potential for success in this novel approach.
Where this research is happening
Cincinnati, United States
- Mc1r Ventures LLC — Cincinnati, United States (Active)
Researchers
- Principal investigator: Abdel-Malek, Zalfa — Mc1r Ventures LLC
- Study coordinator: Abdel-Malek, Zalfa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.